Literature DB >> 17367063

Synergistic cytotoxicity through the activation of multiple apoptosis pathways in human glioma cells induced by combined treatment with ionizing radiation and tumor necrosis factor-related apoptosis-inducing ligand.

Motoo Nagane1, Webster K Cavenee, Yoshiaki Shiokawa.   

Abstract

OBJECT: Malignant gliomas remain incurable despite modem multimodality treatments. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, a member of the TNF family, preferentially induces apoptosis in human tumor cells through its cognate death receptors DR4 or DR5, suggesting that it may serve as a potential therapeutic agent for intractable malignant gliomas. Here, the authors show that genotoxic ionizing radiation synergistically enhances TRAIL-induced cell death in human glioma cells expressing DR5.
METHODS: Combination treatment with soluble human TRAIL plus radiation induced robust cell death, while each of them singly led to only limited cytotoxicity. The combination resulted in cleavage and activation of the apoptotic initiator caspase-8 and the effector caspase-3 as well as cleavage of Bid and another initiator caspase-9, a downstream component of the apoptosome. Accordingly, it augmented the release of cytochrome c from the mitochondria into the cytosol, as well as apoptosis-inducing factor. Synergistic cell death was suppressed by TRAIL-neutralizing DR5-Fc, caspase inhibitors, expression of dominant-negative Fas-associated protein with death domain and CrmA, which selectively blocks caspase-8, and overexpression of Bcl-X(L). Finally, combination treatment had no influence on the viability of normal human astrocytes.
CONCLUSIONS: These results suggest that combination treatment with TRAIL and ionizing radiation kills human glioma cells through the activation of DR5-mediated death receptor pathways. This therapy involves direct activation of effector caspases as well as mitochondria-mediated pathways and provides a novel strategy in which TRAIL could be synergistically combined with DNA-damaging radiation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367063     DOI: 10.3171/jns.2007.106.3.407

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Regulating the expression of therapeutic transgenes by controlled intake of dietary essential amino acids.

Authors:  Cédric Chaveroux; Alain Bruhat; Valérie Carraro; Céline Jousse; Julien Averous; Anne-Catherine Maurin; Laurent Parry; Florent Mesclon; Yuki Muranishi; Pierre Cordelier; Aline Meulle; Patrick Baril; Anh Do Thi; Philippe Ravassard; Jacques Mallet; Pierre Fafournoux
Journal:  Nat Biotechnol       Date:  2016-06-06       Impact factor: 54.908

2.  Cisplatin-enhanced sensitivity of glioblastoma multiforme U251 cells to adenovirus-delivered TRAIL in vitro.

Authors:  Jian Chen; Xiaobai Sun; Weihua Yang; Guosheng Jiang; Xingang Li
Journal:  Tumour Biol       Date:  2010-07-11

3.  TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo.

Authors:  Benny Perlstein; Susan A Finniss; Cathie Miller; Hana Okhrimenko; Gila Kazimirsky; Simona Cazacu; Hae Kyung Lee; Nancy Lemke; Shlomit Brodie; Felix Umansky; Sandra A Rempel; Mark Rosenblum; Tom Mikklesen; Shlomo Margel; Chaya Brodie
Journal:  Neuro Oncol       Date:  2012-11-08       Impact factor: 12.300

4.  Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK.

Authors:  Sahdeo Prasad; Vivek R Yadav; Ramaswamy Kannappan; Bharat B Aggarwal
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

5.  Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

Authors:  Motoo Nagane; Saki Shimizu; Eiji Mori; Shiro Kataoka; Yoshiaki Shiokawa
Journal:  Neuro Oncol       Date:  2010-02-11       Impact factor: 12.300

6.  FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors.

Authors:  Ivy A Ho; Wai H Ng; Paula Y Lam
Journal:  Mol Cancer       Date:  2010-10-13       Impact factor: 27.401

7.  The interruption of PKC-ι signaling and TRAIL combination therapy against glioblastoma cells.

Authors:  Andrea N McCray; Shraddha Desai; Mildred Acevedo-Duncan
Journal:  Neurochem Res       Date:  2014-06-26       Impact factor: 3.996

Review 8.  Role of nanotechnology and gene delivery systems in TRAIL-based therapies.

Authors:  George E Naoum; Fady Tawadros; Ammad Ahmad Farooqi; Muhammad Zahid Qureshi; Sobia Tabassum; Donald J Buchsbaum; Waleed Arafat
Journal:  Ecancermedicalscience       Date:  2016-08-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.